Evidence map›Paper›PMID 30798394›Full record

ArticleInternational journal of clinical oncology2019

Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.

Daisuke Furuya, Mikako Moriai, Yuki Koizumi, Teruo Endo, Kouichi Asanuma, Nozomi Yanagihara, Satoshi Takahashi

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Daisuke FuruyaDivision of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan.ORCID http://orcid.org/0000-0001-7953-8935
Mikako MoriaiDivision of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan.
Yuki KoizumiDivision of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan.
Teruo EndoDivision of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan.
Kouichi AsanumaDivision of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan.
Nozomi YanagiharaDivision of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan.
Satoshi TakahashiDivision of Laboratory Medicine, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan. stakahas@sapmed.ac.jp.
Sapporo Medical University Hospital · JPSapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor BCR-ABL1 mRNA in patients with chronic myeloid leukemia (CML) has generally been analysed by real-time polymerase chain reaction (PCR). Application of the international scale (IS) for the quantification of major BCR-ABL1 mRNA has been recommended in several sets of guidelines, including those of the European LeukemiaNet. The aim of this study was to clarify the efficacy of digital PCR technology for the IS of BCR-ABL1 mRNA in the patients with CML by comparing with real-time PCR.

methodsThe analysis of BCR-ABL1 mRNA was carried out by the Ipsogen

resultsThe correlation between the data obtained by digital PCR and by real-time PCR was really high at R = 0.96. The detection limit of digital PCR was up to 0.003% and was equal to IS with 0.01% or less in comparison with real-time PCR.

conclusionsDigital PCR technology is promising for predicting the IS value with similar efficacy to real-time PCR and should be useful for simple monitoring of the effects of tyrosine kinase inhibitor (TKI) treatments.

Indexed as

Biomarkers, TumorFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLimit of DetectionProtein Kinase InhibitorsReal-Time Polymerase Chain ReactionReference StandardsRNA, MessengerRNA, NeoplasmBCR-ABL1 fusion protein, humanBiomarkers, TumorFusion Proteins, bcr-ablProtein Kinase InhibitorsRNA, MessengerRNA, NeoplasmChronic myeloid leukemia (CML)Digital PCRInternational scale (IS)Major BCR-ABL1Real-time PCR

Identifiers

PMID30798394
OpenAlexW2917638547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.